Evaluation of Angiogenesis Parameters and Tumor Markers in Inflammatory Breast Cancer Specimens
Inflammatory breast carcinoma (IBC) is an extremely rare, aggressive form of breast cancer
that disproportionately affects young women. The risk factors and pathogenesis of these
tumors are unknown and it is unclear whether tumors showing various clinical, pathological
or molecular features behave differently. IBC appears to be a highly angiogenic tumor. In
this study, tumor markers and parameters of angiogenesis will be further investigated in
The Inflammatory Breast Cancer Registry and Biospecimen Repository is a project funded by a
grant from the Department of Defense to Paul H. Levine at GWUMC. The purpose of the
registry is to develop a national registry of patients with IBC that will contain
standardized clinical, epidemiological, and pathological information, along with recurrence
and survival data. The goal is to obtain specimens from approximately 150 patients with
IBC. The data in the registry and repository will be made available to researchers to aid
in the development of a clinicopathological diagnosis of IBC. Investigators at GWUMC will
consent recruited patients and collect clinical data. Subjects will not be recruited,
evaluated, or monitored at the NCI. The GWUMC IRB will oversee human subjects protection
issues. All samples obtained from GWUMC will be blinded and coded to the NCI investigators.
In addition to the samples from George Washington University, we will obtain 150 control
samples from the National Cancer Institute Cooperative Breast Cancer Tissue Resource. These
samples were not available when this protocol was first submitted.
In collaboration with George Washington University Medical Center (GWUMC), we plan to test
tissue specimens collected in the IBC registry and biospecimen repository. We will obtain
frozen tissue (tissue and/or normal) and paraffin-embedded tissue blocks from each case.
Genetic testing will not be performed on any of the samples. One pathologist reviews cases
for grade and lymphovascular invasion (LVI) based on H& E staining. Specimens will be
tested for biological markers associated with IBC to help in classification of these tumors.
These include ER, E-cadherin, podoplanin, ReIB, RhoC and vasodilator-stimulated
phosphoprotein (VASP). Angiogenesis parameters will also be evaluated. These include
hypoxia-inducible factor 1 alpha (HIF-1 alpha), vascular endothelial growth factor D
(VEGF-D) protein expression, VEGF-C protein expression, VEGF-receptor 2 (VEGFR-2, Kdr) or
VEGF-receptor 3 (VEGFR-3, flt-4).
Amy Subar, Ph.D.
National Cancer Institute (NCI)
United States: Federal Government
|GW University Medical Center GW Hospital Center||Washington, District of Columbia 20037|